Open access · US-GOV
via ClinicalTrials.gov Clinical trial
STI 571 (GLIVEC) in the Treatment of Philadelphia-chromosome Positive and/or BCR/ABL Rearranged Adult Acute Lymphoblastic Leukemia. GIMEMA LAL 0201.
Authors not listed
Gruppo Italiano Malattie EMatologiche dell'Adulto · 2001
Abstract
This proposal, developed in the framework of the GIMEMA, will permit:
* to evaluate the activity and toxicity of imatinib in the treatment of Ph+ acute lymphoblastic leukemia;
* to evaluate the molecular response to the treatment, and to monitor the molecular status of remission in all cases achieving or not a molecular response.
The GIMEMA has activated a network to centralize all biological samples (bone marrow and peripheral blood) at diagnosis from all new ALL patients. This will permit to identify, in particular, Ph + and/or BCR/ABL + cases within 5 days from diagnosis, thus permitting to treat these patients according to different programs on the basis of the presence of Ph chromosome.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-25 MST
Cite this
APA
Anonymous. (2001). STI 571 (GLIVEC) in the Treatment of Philadelphia-chromosome Positive and/or BCR/ABL Rearranged Adult Acute Lymphoblastic Leukemia. GIMEMA LAL 0201. <em>Gruppo Italiano Malattie EMatologiche dell'Adulto</em>. https://clinicaltrials.gov/study/NCT00376467
Vancouver
Anonymous. STI 571 (GLIVEC) in the Treatment of Philadelphia-chromosome Positive and/or BCR/ABL Rearranged Adult Acute Lymphoblastic Leukemia. GIMEMA LAL 0201. Gruppo Italiano Malattie EMatologiche dell'Adulto. 2001.
BibTeX
@misc{anon2001STIGLI,
title = {STI 571 (GLIVEC) in the Treatment of Philadelphia-chromosome Positive and/or BCR/ABL Rearranged Adult Acute Lymphoblastic Leukemia. GIMEMA LAL 0201.},
author = {Anonymous},
journal = {Gruppo Italiano Malattie EMatologiche dell'Adulto},
year = {2001},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nicola Goekbuget 2018
Open access · US-GOV
Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Followed by Chemotherapy Consolidation and Maintenance Therapy In Patients Aged 56 Years and Older With Acute Lymphoblastic Leukemia (ALL)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 2021
Open access · US-GOV
The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia
Versailles Hospital 2007
Open access · US-GOV
An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Dasatinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL).
The Affiliated Hospital of Hangzhou Normal University 2026
Open access · US-GOV
A Single-Center, Prospective, Observational Registry Cohort Study to Investigate Aging-Related Biomarkers, Prognosis, and Risk Prediction in Patients With Acute Myocardial Infarction
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2019
Open access · US-GOV
Up-front Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia Aged 65-75
Nicotine & Tobacco Research 2009
Open access · OA